Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: Estimates from the PreEMPT model.

导出 OA

翻译打印收藏纠错

作者： Kurt D,Christensen ^[1] ; Pamela M,McMahon ^[2] ; Lauren N,Galbraith ^[3] ; Jennifer M,Yeh ^[4] ; Natasha K,Stout ^[5] ; Christine Y,Lu ^[5] ; Sarah,Stein ^[2] ; Maryann,Zhao ^[6] ; Robyn J,Hylind ^[7] ; Ann Chen,Wu ^[8]

作者单位： Department of Population Medicine, Harvard Medical School, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA. Electronic address: kurt_christensen@harvardpilgrim.org. ^[1] Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA. ^[2] Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA; Department of Epidemiology and Biostatistics, School of Public Health, Boston University, Boston, MA. ^[3] Division of General Pediatrics, Department of Pediatrics, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA. ^[4] Department of Population Medicine, Harvard Medical School, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA. ^[5] Harvard Medical School, Boston, MA. ^[6] Inherited Cardiac Arrhythmia Program, Department of Cardiology, Boston Children's Hospital Boston, MA. ^[7] Department of Population Medicine, Harvard Medical School, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA; Division of General Pediatrics, Department of Pediatrics, Boston Children's Hospital, Boston, MA. ^[8]

关键词 Cost-effectiveness analysis Genetic testing Hypertrophic cardiomyopathy Neonatal screening Sudden cardiac death